Back to Search
JARMIN MIKHAEL, MD
MD
Internal Medicine Physician
NPI: 1134869530IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
4301514165(MI)57.252784(OH)
Education
OTHER
Class of 2014
Research & Publications (18)
High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.
PMID 19036114·Br J Haematol·2009
3-trial
Using a pocket card to improve end-of-life care on internal medicine clinical teaching units: a cluster-randomized controlled trial.
PMID 18446415·J Gen Intern Med·2008
4-observational
Canadian supportive care recommendations for the management of anemia in patients with cancer.
PMID 17938704·Curr Oncol·2007
8-other
Resident preparedness in discussing prognosis in patients with advanced lung cancer.
PMID 19629536·Support Care Cancer·2010
8-other
Predictors of mortality in patients undergoing autologous hematopoietic cell transplantation admitted to the intensive care unit.
PMID 18936734·Bone Marrow Transplant·2009
8-other
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.
PMID 19225538·Leukemia·2009
3-trial
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone.
PMID 19324902·Blood·2009
8-other
Safety and efficacy results from an international expanded access programme to bortezomib for patients with relapsed and/or refractory multiple myeloma: a subset analysis of the Australian and New Zealand data of 111 patients.
PMID 19371392·Intern Med J·2009
4-observational
Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant.
PMID 19450753·Biol Blood Marrow Transplant·2009
8-other
Canadian supportive care recommendations for the management of neutropenia in patients with cancer.
PMID 18317581·Curr Oncol·2008
8-other
Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma.
PMID 18645194·J Clin Oncol·2008
3-trial
Feasibility and safety of autotransplants with noncryopreserved marrow or peripheral blood stem cells: a systematic review.
PMID 17355952·Ann Oncol·2007
1-meta
Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance.
PMID 16129840·J Clin Oncol·2005
8-other
Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation.
PMID 16113669·Bone Marrow Transplant·2005
8-other
Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation.
PMID 16342650·Mayo Clin Proc·2005
8-other
Outpatient total body irradiation as a component of a comprehensive outpatient transplant program.
PMID 12180111·Bone Marrow Transplant·2002
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1447 N HARRISON ST
SAGINAW, MI 48602 - Phone
- (989) 583-4220
Quick Facts
- NPI
- 1134869530
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 12
- Publications
- 18
Are you this provider?
Claim Your Profile